ATE524479T1 - Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren - Google Patents

Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren

Info

Publication number
ATE524479T1
ATE524479T1 AT05731007T AT05731007T ATE524479T1 AT E524479 T1 ATE524479 T1 AT E524479T1 AT 05731007 T AT05731007 T AT 05731007T AT 05731007 T AT05731007 T AT 05731007T AT E524479 T1 ATE524479 T1 AT E524479T1
Authority
AT
Austria
Prior art keywords
sulfonamidthiazolepyridine
glucokinase
activations
diabetes
derivatives
Prior art date
Application number
AT05731007T
Other languages
English (en)
Inventor
Gregory Bebernitz
Ramesh Gupta
Vikrant Jagtap
Appaji Mandhare
Davinder Tuli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE524479T1 publication Critical patent/ATE524479T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05731007T 2004-04-02 2005-04-01 Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren ATE524479T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55918404P 2004-04-02 2004-04-02
PCT/EP2005/003456 WO2005095418A1 (en) 2004-04-02 2005-04-01 Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes

Publications (1)

Publication Number Publication Date
ATE524479T1 true ATE524479T1 (de) 2011-09-15

Family

ID=34963913

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05731007T ATE524479T1 (de) 2004-04-02 2005-04-01 Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren

Country Status (19)

Country Link
US (1) US7750020B2 (de)
EP (1) EP1735322B1 (de)
JP (1) JP4700684B2 (de)
KR (1) KR100830007B1 (de)
CN (1) CN1960995B (de)
AR (1) AR050913A1 (de)
AT (1) ATE524479T1 (de)
AU (1) AU2005229416B2 (de)
BR (1) BRPI0509573A (de)
CA (1) CA2560689C (de)
EC (1) ECSP066894A (de)
IL (1) IL178151A0 (de)
MA (1) MA28528B1 (de)
NO (1) NO20064929L (de)
PE (1) PE20061353A1 (de)
PT (1) PT1735322E (de)
RU (1) RU2412192C2 (de)
TN (1) TNSN06315A1 (de)
WO (1) WO2005095418A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2006509774A (ja) * 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1737870A1 (de) * 2004-04-02 2007-01-03 Novartis AG Thiazolopyridinderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zur behandlung von durch glucokinase vermittelten leiden
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
EP1951707A1 (de) * 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Substituierte pyrrolone als allostere modulatoren von glucokinase
WO2007053765A2 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
US8796313B2 (en) 2005-11-01 2014-08-05 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
EP1951706A1 (de) * 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolone als allosterische modulatoren von glucokinase
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2657566A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
CN101687800B (zh) * 2007-03-07 2012-03-21 杏林制药株式会社 葡糖激酶活化物质
WO2008119734A2 (en) * 2007-03-29 2008-10-09 Novartis Ag Process for the manufacture of organic compounds
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CA2700783C (en) * 2007-10-08 2015-03-17 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
CN101417987B (zh) * 2007-10-24 2011-07-13 山东轩竹医药科技有限公司 具有磺酰胺甲酰哌嗪结构的dpp-iv抑制剂
AU2009205070A1 (en) 2008-01-18 2009-07-23 Astellas Pharma Inc. Phenyl acetamide derivative
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
MY163114A (en) * 2008-04-28 2017-08-15 Kyorin Seiyaku Kk Cyclopentylacrylamide derivative
TWI445707B (zh) 2008-05-16 2014-07-21 Takeda California Inc 葡萄糖激酶活化劑
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
WO2010144909A1 (en) * 2009-06-12 2010-12-16 Novartis Ag Fused heterocyclic compounds and their uses
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013173382A1 (en) * 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
EP2909194A1 (de) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
EP3236959B1 (de) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (de) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Hemmer von cyclinabhängigen kinasen
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2242469C2 (ru) 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
HRP20010688B1 (en) 1999-03-29 2008-10-31 F. Hoffmann - La Roche Ag Glucokinase activators
US6320050B1 (en) 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
PT1282612E (pt) 2000-05-03 2005-04-29 Hoffmann La Roche Actividades heteroaromaticas da glucoquinase a vase de alcinilo-fenilo
CN1209361C (zh) 2000-05-03 2005-07-06 霍夫曼-拉罗奇有限公司 含乙内酰脲的葡糖激酶激活剂
DE60134470D1 (de) 2000-05-08 2008-07-31 Hoffmann La Roche Para-amin substituierte phenylamid glukokinase activatoren
US6489485B2 (en) 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
JP3839723B2 (ja) 2000-05-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 置換フェニルアセトアミドおよびグルコキナーゼ活性化剤としてのその使用
AU2001287600B2 (en) 2000-07-20 2006-07-13 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
ATE316965T1 (de) 2000-12-06 2006-02-15 Hoffmann La Roche Kondensierte heteroaromatische glucokinaseaktivatoren
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
RU2374236C2 (ru) 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
EP1496052B1 (de) 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Neue aminobenzamidderivate
DK1501815T3 (da) 2002-04-26 2007-04-02 Hoffmann La Roche Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
JPWO2003097824A1 (ja) 2002-05-16 2005-09-15 萬有製薬株式会社 グルコキナーゼタンパク質の結晶、及びその結晶を用いたドラッグデザイン方法
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
CA2499329C (en) 2002-10-03 2009-04-21 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
JP2006509774A (ja) * 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
JP4716734B2 (ja) 2003-01-06 2011-07-06 イーライ リリー アンド カンパニー グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
WO2004063194A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
WO2004076420A1 (ja) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
EP1737870A1 (de) 2004-04-02 2007-01-03 Novartis AG Thiazolopyridinderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zur behandlung von durch glucokinase vermittelten leiden
AU2005235798A1 (en) 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
AU2005311269B2 (en) 2004-12-03 2011-11-10 Transtech Pharma, Inc. Heteroaromatic glucokinase activators
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos

Also Published As

Publication number Publication date
KR100830007B1 (ko) 2008-05-15
WO2005095418A1 (en) 2005-10-13
ECSP066894A (es) 2006-11-24
BRPI0509573A (pt) 2007-09-25
CA2560689A1 (en) 2005-10-13
TNSN06315A1 (en) 2007-12-03
IL178151A0 (en) 2006-12-31
NO20064929L (no) 2006-12-20
CN1960995B (zh) 2010-12-08
CN1960995A (zh) 2007-05-09
AU2005229416B2 (en) 2009-03-26
JP2007530632A (ja) 2007-11-01
EP1735322A1 (de) 2006-12-27
PE20061353A1 (es) 2006-12-29
RU2006138433A (ru) 2008-05-10
MA28528B1 (fr) 2007-04-03
RU2412192C2 (ru) 2011-02-20
PT1735322E (pt) 2012-01-12
AU2005229416A1 (en) 2005-10-13
US20080103167A1 (en) 2008-05-01
EP1735322B1 (de) 2011-09-14
JP4700684B2 (ja) 2011-06-15
CA2560689C (en) 2011-03-01
KR20060131955A (ko) 2006-12-20
AR050913A1 (es) 2006-12-06
US7750020B2 (en) 2010-07-06

Similar Documents

Publication Publication Date Title
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
EP1755661A4 (de) Verwendung von gelsolin zur behandlung von infektionen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE494279T1 (de) Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
EP1758597A4 (de) Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
ATE371451T1 (de) Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EP1742675A4 (de) Behandlung von biomedizinischem abfall
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties